Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEMETREXED DITROMETHAMINE vs PEMETREXED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent purine and pyrimidine synthesis, leading to disruption of DNA synthesis and cell death.
Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. It inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), leading to inhibition of de novo purine and pyrimidine synthesis.
FDA-approved: In combination with cisplatin for initial treatment of patients with malignant pleural mesothelioma who are unresectable or not surgical candidates.,FDA-approved: As a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior platinum-based chemotherapy.,FDA-approved: In combination with pembrolizumab and platinum chemotherapy for first-line treatment of metastatic non-squamous NSCLC.,Off-label: Treatment of recurrent or metastatic cervical cancer, breast cancer, bladder cancer, colorectal cancer, and others.
Malignant pleural mesothelioma (in combination with cisplatin),Non-small cell lung cancer (NSCLC) - first-line treatment (in combination with cisplatin),NSCLC - maintenance therapy (after platinum-based chemotherapy),NSCLC - second-line treatment (single agent)
500 mg/m2 intravenously over 10 minutes every 21 days.
500 mg/m2 IV over 10 minutes on Day 1 of each 21-day cycle, with folic acid and vitamin B12 supplementation.
Terminal half-life 3.5 hours (range 2.5-5.0 hours) in patients with normal renal function; prolonged to 5-10 hours in moderate renal impairment. Clinical context: Half-life is dose-independent; clearance correlates with creatinine clearance.
Terminal half-life is approximately 3.5 hours in patients with normal renal function (creatinine clearance ≥60 m L/min). Clinically, half-life is prolonged in renal impairment (up to 20 hours in severe impairment), requiring dose adjustment.
Pemetrexed is primarily excreted unchanged in the urine. It undergoes minimal hepatic metabolism; less than 5% is metabolized by the liver.
Pemetrexed is primarily eliminated unchanged in the urine. It undergoes minimal hepatic metabolism. Renal excretion accounts for approximately 70-90% of elimination.
Primarily renal excretion: 70-90% of the dose is eliminated unchanged in urine within 24 hours. Fecal excretion accounts for <5%.
Primarily eliminated unchanged in urine (70-90% of dose via renal excretion over 24 hours); minimal biliary/fecal excretion (<5%).
81% bound primarily to albumin; minimal binding to alpha-1-acid glycoprotein.
Approximately 81% bound to plasma proteins, primarily albumin (given its structure as a folate analog).
Vd at steady state = 16.1 L/m² (approximately 0.4 L/kg in adults). Clinical meaning: Indicates distribution into total body water with limited tissue binding; low Vd suggests minimal extravascular distribution.
Volume of distribution is about 16.1 L/m² (total body water); in weight-based terms ~0.3-0.4 L/kg, indicating limited tissue distribution consistent with a polar molecule.
Intravenous only; bioavailability is 100% by IV route. Not orally available due to poor absorption and extensive first-pass metabolism.
Only administered intravenously; oral bioavailability is negligible (<1%) due to poor intestinal absorption and first-pass metabolism, thus no oral formulation available.
Cr Cl ≥45 m L/min: 500 mg/m2; Cr Cl 30-44 m L/min: 375 mg/m2; Cr Cl <30 m L/min: not recommended.
Cr Cl ≥45 m L/min: no adjustment. Cr Cl <45 m L/min: not recommended; consider dose reduction to 500 mg/m2 if Cr Cl 40–45 m L/min with close monitoring; do not use if Cr Cl <40 m L/min.
No dose adjustment recommended for Child-Pugh A or B. Child-Pugh C: no data.
Child-Pugh A and B: no adjustment. Child-Pugh C: insufficient data; use with caution.
Not established; safety and efficacy not determined in pediatric patients.
Not FDA approved; limited data: 500 mg/m2 IV over 10 minutes Day 1 every 21 days, with folic acid and B12 supplementation, based on adult protocol. Weight-based for patients <1.5 m²: calculate BSA and dose accordingly.
No specific dose adjustment; monitor renal function closely due to age-related decline in Cr Cl.
No specific dose adjustment; monitor renal function (Cr Cl) due to age-related decline; ensure folic acid and vitamin B12 supplementation.
Pemetrexed can cause severe or fatal hypersensitivity reactions, including anaphylaxis. It also causes severe myelosuppression, which may require dose modification or discontinuation. Patients must be pretreated with corticosteroids and vitamin supplementation to reduce toxicity.
Pemetrexed can cause severe and sometimes fatal myelosuppression, renal failure, and severe gastrointestinal toxicity. Patients must be pretreated with corticosteroids and folic acid and vitamin B12 to reduce toxicity.
Myelosuppression: Dose-dependent, monitor blood counts regularly.,Renal toxicity: Excreted renally; adjust dose in renal impairment (Cr Cl <45 m L/min).,Gastrointestinal toxicity: Nausea, vomiting, diarrhea; may require antiemetics.,Hypersensitivity reactions: Premedicate with corticosteroids.,Folic acid and vitamin B12 deficiency: Supplement to reduce hematologic toxicity.,Third-space fluid accumulation: Consider drainage before treatment.
Bone marrow suppression (including neutropenia, thrombocytopenia, anemia); renal toxicity (monitor renal function); gastrointestinal toxicity (e.g., diarrhea, mucositis); dermatologic reactions (e.g., rash, exfoliation); radiation recall reactions; increased risk of toxicity in patients with pleural effusion or ascites (consider drainage); embryo-fetal toxicity.
History of severe hypersensitivity reaction to pemetrexed or any excipients.,Concurrent yellow fever vaccine (risk of systemic fatal disease).,Severe renal impairment (Cr Cl <45 m L/min) not meeting criteria for dose adjustment.
History of severe hypersensitivity reaction to pemetrexed; concomitant administration of yellow fever vaccine; severe renal impairment (creatinine clearance <45 m L/min) (relative contraindication due to increased toxicity).
No specific dietary restrictions. However, folic acid supplements and vitamin B12 are required. Avoid folic acid antagonists like methotrexate.
No specific food interactions are documented. However, patients should maintain adequate folic acid intake through diet and supplements as prescribed. Avoid grapefruit or grapefruit juice? There is no known interaction with grapefruit. Patients should maintain a balanced diet and avoid alcohol to prevent liver stress.
Pemetrexed is a folate analog metabolic inhibitor that is teratogenic in animals. In humans, it is contraindicated in pregnancy due to its mechanism of action interfering with DNA synthesis and cell division. First trimester exposure carries the highest risk of major congenital malformations (e.g., neural tube defects, craniofacial anomalies). Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and potential fetal demise. Use in pregnant women is not recommended unless no safer alternative exists.
Pemetrexed is a folate analog antimetabolite that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. It is teratogenic in animal studies at doses below the recommended human dose. In humans, there are no adequate studies in pregnant women; however, based on its mechanism of action, there is potential for fetal harm. First trimester exposure carries the highest risk for major congenital malformations (neural tube, cardiac, skeletal defects). Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. Late pregnancy administration may cause neonatal myelosuppression and toxicity.
There are no data on the presence of pemetrexed in human milk, its effects on the breastfed infant, or milk production. Due to the potential for serious adverse reactions in nursing infants (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is not recommended during pemetrexed therapy and for at least one week after the last dose. The M/P ratio is unknown.
No human data on excretion into breast milk. Pemetrexed is a small molecule (molecular weight 427.46 g/mol) with low protein binding (~81%) and a terminal half-life of 3.5 hours; it is likely excreted into milk. M/P ratio unknown. Due to potential for serious adverse reactions (myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 1 week after last dose.
No specific dosing adjustments for pregnancy are established due to lack of data. Physiologic changes in pregnancy (increased renal clearance, expanded plasma volume) may reduce drug exposure, but dose increases are not recommended due to potential fetal toxicity. In animal studies, lower doses produced embryotoxicity. Therefore, dose adjustments should not be made; the drug should be avoided in pregnancy.
No established dosing guidelines for pregnancy. Physiologic changes (increased renal blood flow, volume of distribution) may reduce pemetrexed exposure, but dose adjustments are not recommended due to lack of safety data. Use only if clearly needed and risk of maternal toxicity outweighs fetal risks. Avoid in first trimester.
Administer folic acid and vitamin B12 supplementation to reduce toxicity. Premedicate with corticosteroids to prevent rash. Monitor renal function; dose adjust for Cr Cl <45 m L/min. Avoid NSAIDs for 2 days before and after dose. Ensure adequate hydration. Do not mix with calcium-containing solutions.
Pemetrexed requires vitamin B12 and folate supplementation to reduce hematologic and gastrointestinal toxicity. Administer folic acid daily (350-1000 mcg) starting 7 days before first dose and continue for 21 days after last dose. Vitamin B12 (1000 mcg IM) should be given 1 week before first dose and repeated every 3 cycles. Contraindicated in patients with creatinine clearance <45 m L/min; dose reduction required for moderate renal impairment. Monitor for severe cutaneous reactions (Stevens-Johnson syndrome) and interstitial pneumonitis. Premedicate with dexamethasone (4 mg PO BID) on the day before, day of, and day after pemetrexed to reduce skin rash incidence.
Take folic acid daily and vitamin B12 injections every 9 weeks as prescribed.,Inform all healthcare providers about your treatment; avoid NSAIDs like ibuprofen or naproxen.,Report new or worsening rash, diarrhea, or mouth sores immediately.,Drink plenty of fluids to stay hydrated.,Avoid receiving live vaccines during treatment.
Take folic acid daily as prescribed, starting 7 days before your first treatment and continuing for 21 days after the last dose.,You will receive a vitamin B12 injection once every three treatment cycles, beginning 1 week before the first dose.,Report any new or worsening shortness of breath, cough, or fever immediately, as this may indicate lung inflammation.,Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or aspirin unless approved by your doctor, especially if you have kidney problems.,Use effective contraception during treatment and for 6 months after the last dose; male patients should avoid fathering a child.,Do not breastfeed while taking this medication.,Stay hydrated and inform your doctor if you experience severe diarrhea, vomiting, or signs of dehydration.,Limit sun exposure and use sunscreen, as pemetrexed may cause photosensitivity.
"Methotrimeprazine may reduce the gastrointestinal absorption of tromethamine, an alkalinizing agent, leading to decreased systemic exposure and potentially diminished therapeutic efficacy. This interaction is hypothesized to occur via altered gastric pH or motility, though direct evidence is limited. Patients may experience reduced effectiveness of tromethamine in managing acid-base disorders."
"Tromethamine, an alkalinizing agent used to correct metabolic acidosis, can increase gastric pH, which may reduce the absorption of weakly acidic drugs like estrone sulfate. This altered gastrointestinal environment can decrease estrone sulfate bioavailability, potentially compromising its systemic effects for hormone replacement therapy. Clinically, this may lead to reduced efficacy of estrone sulfate, requiring dose adjustments or alternative administration routes."
"Tromethamine, an alkalinizing agent, can increase urinary pH, which enhances the renal excretion of sotalol, a class III antiarrhythmic that is primarily eliminated unchanged by the kidneys. This interaction may lead to reduced serum sotalol concentrations, potentially decreasing its therapeutic efficacy and increasing the risk of arrhythmia recurrence, particularly in patients with renal impairment or those requiring precise antiarrhythmic control."
"The risk or severity of adverse effects can be increased when Pemetrexed is combined with Leflunomide."
"Pemetrexed may decrease the cardiotoxic activities of Acetyldigitoxin."
"Pemetrexed may increase the immunosuppressive activities of Fingolimod."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEMETREXED DITROMETHAMINE vs PEMETREXED, answered by our medical review team.
PEMETREXED DITROMETHAMINE is a Antineoplastic Antifolate that works by Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent purine and pyrimidine synthesis, leading to disruption of DNA synthesis and cell death.. PEMETREXED is a Antineoplastic Antifolate that works by Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. It inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), leading to inhibition of de novo purine and pyrimidine synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEMETREXED DITROMETHAMINE and PEMETREXED depend on the specific clinical indication. These are both Antineoplastic Antifolate agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEMETREXED DITROMETHAMINE is: 500 mg/m2 intravenously over 10 minutes every 21 days.. The standard adult dose of PEMETREXED is: 500 mg/m2 IV over 10 minutes on Day 1 of each 21-day cycle, with folic acid and vitamin B12 supplementation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEMETREXED DITROMETHAMINE and PEMETREXED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEMETREXED DITROMETHAMINE is classified as Category C. Pemetrexed is a folate analog metabolic inhibitor that is teratogenic in animals. In humans, it is contraindicated in pregnancy due to its mechanism of action interfering with DNA . PEMETREXED is classified as Category C. Pemetrexed is a folate analog antimetabolite that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. It is teratogenic in ani. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.